Infectious Disease · 1 h ago
Carbapenemase-producing E. coli and K. pneumoniae identified in Peruvian hospitals
A genomic and phenotypic study analyzed 320 isolates collected from four healthcare institutions in Lima, Peru, between 2020 and 2022. NDM was the most common carbapenemase gene, and testing found in-vitro activity of aztreonam/avibactam and cefiderocol against all isolates tested.
- NDM was the most common carbapenemase gene detected.
- All isolates were multidrug-resistant; 5% resisted the routine panel.
- Aztreonam/avibactam and cefiderocol were active in vitro against tested isolates.
- NDM-5 was detected in Peru for the first time.
Researchers characterized 320 non-redundant Escherichia coli (61) and Klebsiella pneumoniae (259) isolates collected from four healthcare institutions in Lima, Peru, between 2020 and 2022. They assessed antimicrobial susceptibility and used polymerase chain reaction and whole-genome sequencing to identify resistance genes and bacterial lineages.
The most frequent carbapenemase gene was blaNDM (69%), followed by blaKPC (16.9%) and blaOXA-48-like (4.6%). Eleven K. pneumoniae isolates carried both NDM and KPC, while one E. coli isolate carried NDM and OXA-48-like. All isolates were multidrug-resistant, and 5% were resistant to every agent in the routine panel. Aztreonam/avibactam and cefiderocol showed in-vitro activity against all tested isolates. The study also identified blaNDM-5 in Peru for the first time, mostly in E. coli ST167, and found K. pneumoniae ST147 associated with blaNDM-1.
These findings document resistance patterns and high-risk lineages in the sampled hospitals, supporting the authors’ call for genomic surveillance and antimicrobial stewardship. The results are limited to isolates from four institutions and in-vitro testing; they do not establish clinical effectiveness of the tested drugs.
Is this summary clinically accurate?
Help fellow clinicians: your rating sends inaccurate summaries straight to our editors.
Sign in to rate this summary →Source
Antimicrobial Agents and Chemotherapy: Expanding threat of carbapenemase-producing Escherichia coli and Klebsiella pneumoniae in Peru: genomic and phenotypic evidence of high-risk clones dissemination ↗This is an automated AI-condensed summary that has not yet been reviewed by an editor. Always consult the full item at the original source.